Patientengefährdung durch DDAVP?

• Literatur

• 1 Miesbach Dück. Llugaliu et al. Hämostaseologie. 2009; 29 (Suppl. 01) S46-S47.
• 2 Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Journal Prog Hemost Thromb 1986; 08: 19-45.
• 3 Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318: 121.
• 4 Franchini M, Krampera M, Veneri D. Deep vein thrombosis after orthopedic surgery in a patient with type 1 Willebrand disease and mutation in the MTHFR and beta-fibrinogengenes. ThrombHaemost 2003; 90: 963.
• 5 Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-2521.
• 6 Cattaneo M, Harris AS, Strömberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery--a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost 1995; 74: 1064-1070.
• 7 Levi M, Cromheecke ME, de Jonge E. et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically releveant endpoints. Lancet 1999; 354: 1940-1947.
• 8 Cattaneo M. The use of desmopressin in open-heart surgery. Haemophilia 2008; 14 (Suppl. 01) 40-47.